Lens / cognition-neuro
Sermorelin Cognition: What GHRH Trials in Older Adults Show
The strongest cognition signal comes from a controlled trial of a GHRH analog — with one caveat stated up front: most of this evidence uses related analogs, not sermorelin itself.
The short version
Sermorelin cognition is a real research question, with one honest limit. Sermorelin copies GHRH (the brain's "make growth hormone" signal), and that signalling system reaches the brain. In a controlled trial, a close cousin of sermorelin — a longer-lasting GHRH analog — improved thinking scores in older adults over 20 weeks [6]. In mice, other GHRH-class molecules lowered the proteins linked to Alzheimer's [7]. The catch: most of this work used related analogs, not sermorelin itself. So this describes GHRH-axis effects measured in studies — not a proven brain benefit of sermorelin in people.
The controlled cognition trial
The anchor finding is a randomized, double-blind, placebo-controlled trial of 152 older adults, 66 of them with mild cognitive impairment. Over 20 weeks, daily subcutaneous GHRH analog (tesamorelin, 1 mg before bedtime) had a favorable effect on cognition (P=0.03), with the effect strongest on executive function (P=0.005) [6]. The same trial raised IGF-1 by 117% — kept within the physiologic range — and reduced percent body fat by 7.4%, with adverse events characterized as mild [6]. It is registered as NCT00257712.
Two points keep the finding honest. The tested molecule was tesamorelin, a stabilized GHRH analog, not GHRH(1-29) itself. And a favorable effect over 20 weeks in a single trial is a signal worth documenting, not a settled claim about preventing cognitive decline.
The preclinical neuro tail
Below the human trial sits a set of animal and cell findings on GHRH-class molecules. In genetically modified 5XFAD Alzheimer's mice, the GHRH antagonist MIA-690 reduced Morris-water-maze escape latency and lowered brain amyloid-beta(1-42) and tau filament levels; in amyloid-beta-treated human HCN2 cortical cell cultures, a GHRH analog showed anti-oxidative, neuroprotective properties [7]. Administered into the lateral brain ventricle in mice, the GHRH antagonist MZ-4-71 improved consolidation of passive-avoidance learning, fully blocked beta-amyloid(25-35)-induced memory impairment, and produced antidepressant-like and mild anxiolytic effects without altering locomotion [8].
That both agonist and antagonist GHRH analogs appear neuroprotective in different models reflects how complex the axis is — a complexity catalogued in a 2025 Nature Reviews Endocrinology synthesis of GHRH biology across health and disease [12]. A 2026 rat study added a frontier signal: a sustained-release GHRH receptor agonist (MR-409, 10 mcg/rat/day) combined with mesenchymal stem cells resolved post-stroke vasogenic edema and reduced infarct size [13]. None of these are sermorelin clinical trials.
The GH/IGF-1 axis and the aging brain
The rationale connecting GHRH to cognition runs through IGF-1. A narrative review frames IGF-1 as a neurotrophic, neuroprotective factor and the GH/IGF-1 axis as a candidate therapeutic target in Alzheimer's disease — while noting GH responses to GHRH stimulation in Alzheimer's patients are equivocal, and that the cholinesterase inhibitor rivastigmine doubled the GH response to GHRH [9].
A counterweight comes from human imaging. In 13 adults with lifelong, untreated isolated GH deficiency from a GHRH-receptor gene mutation, versus 14 matched controls, MRI brain morphometry showed largely similar cortical thickness and regional volumes, and similar MRI-predicted versus chronological brain age [14]. Lifelong loss of GHRH-receptor signalling, in other words, did not appear to accelerate brain aging — a reminder that the axis's role in cognition is far from simple.
Lens questions
Two questions sit directly under the cognition lens.